AstraZeneca / Alexion Pharmaceuticals merger inquiry
The CMA investigated and cleared the anticipated acquisition by AstraZeneca plc of Alexion Pharmaceuticals, Inc.
Statutory timetable
| Phase 1 date | Action |
|---|---|
| 14 July 2021 | Decision announced |
| 21 July 2021 | Deadline for phase 1 decision |
| 25 May 2021 to 3 June 2021 | Invitation to comment |
| 25 May 2021 | Launch of merger inquiry |
Phase 1
CMA clearance decision
14 July 2021: The CMA has cleared the anticipated acquisition by AstraZeneca plc of Alexion Pharmaceuticals, Inc.
- (18.8.21)
Launch of merger inquiry
25 May 2021: The CMA announced the launch of its merger inquiry by notice to the parties.
- (25.5.21)
Invitation to comment: closed 3 June 2021
25 May 2021: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
To assist it with this assessment, the CMA invites comments on the transaction from any interested party.
These comments should be provided by the deadline set out above.
Contact
Please send written representations about any competition issues to:
Updates to this page
Published 25 May 2021Last updated 18 August 2021 + show all updates
-
Full text decision published.
-
Clearance decision announced.
-
First published.